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Research in context 
Evidence before this study 
Cross sectional imaging is fundamental for diagnosis and management of Crohn’s disease 
and is replacing barium fluoroscopic techniques which have been the bedrock of small bowel 
imaging for many years. Dissemination of cross sectional imaging has however occurred 
despite a paucity of supportive data from prospective multi centre studies recruiting 
consecutive and unselected patients. Emphasis is placed on magnetic resonance imaging 
enterography (MRE) and enteric ultrasound (US) as they avoid ionising radiation. Clinical 
uptake of US has been hampered by concerns over diagnostic accuracy and perceived high 
levels of inter-observer variation.   MRE is a more recent innovation necessitating access to 
comparatively restricted high technology imaging platforms. We searched PubMed and 
Embase in Jan 2018 for articles between Jan 1
st
 1990 and Dec 1
st
 2017 without language 
restriction. We used MeSH and full-text search for “Crohn’s disease”, “magnetic resonance 
imaging”, “ultrasound”, and “diagnostic accuracy”. The primary literature was retrieved but 
emphasis was placed on meta-analyses and systematic reviews using appropriate filters. We 
found a number of meta-analyses, which in general suggest MRE and US have comparable 
sensitivity for detection and activity assessment of small bowel Crohn’s disease. However, 
the primary literature has limitations. Most studies are small single centre explanatory trials 
recruiting fewer than 50 patients. Tests are rarely compared in the same patients, introducing 
bias caused by differences between patients and disease phenotype, and use inconsistent 
reference standards. For example, in a recent meta-analysis, just one of 33 included studies 
compared MRE and US directly in the same patients. Many also rate poorly on the Quality 
Assessment of Diagnostic Accuracy Studies tool. 
Added value of this study 
This is the largest prospective multicenter trial to date comparing the diagnostic accuracy of 
MRE and US for the presence, extent and activity of enteric Crohn’s disease, using a 
construct reference standard incorporating 6 months of patient follow up. We used a 
pragmatic trial design to better assess test performance in routine clinical practice, and used 
the preferred methodology for diagnostic accuracy studies, by comparing tests in the same 
patients. Both tests achieved high accuracy for detecting and localising small bowel Crohn’s 
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disease, but sensitivity and specificity for small bowel disease presence and extent was 
significantly greater for MRE than US. 
Implications of all the available evidence 
Both US and MRE achieve high diagnostic accuracy for the extent and activity of small 
bowel Crohn’s disease in both newly diagnosed patients and those suffering relapse. Whilst 
both tests are valid first-line investigations, MRE is generally the preferred radiological 
investigation when available because its sensitivity and specificity exceed US significantly 
when tested in a prospective multi-center trial setting. Future research should investigate the 
role of cross sectional imaging in patients with nonspecific abdominal symptoms without an 
established diagnosis of Crohn’s disease, and the complimentary role of MRE and US in 
targeted follow up of Crohn’s disease patients with an established disease phenotype. 
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Abstract  
Background 
Magnetic resonance enterography (MRE) and ultrasound (US) are used to image Crohn’s 
disease, but comparative accuracy for disease extent and activity is not known with certainty. 
We undertook a prospective multicentre cohort trial to address this  
Methods 
We recruited from 8 UK hospitals. Eligible patients were 16 years or older, newly diagnosed 
with Crohn’s disease, or had established disease with suspected relapse. Consecutive patients 
underwent MRE and US in addition to standard investigations.  Discrepancy between MRE 
and US for small bowel (SB) disease presence triggered an additional investigation, if not 
already available. The primary outcome was difference in per patient sensitivity for SB 
disease extent (correct identification and segmental localisation) against a construct reference 
standard (panel diagnosis).  Accuracy for SB and colonic disease presence and activity were 
secondary outcomes. The trial is completed (ISRCTN03982913). 
Findings 
284 patients completed the trial (133 new diagnosis, 151 relapse). MRE sensitivity (n=233) 
for SB disease extent (80% [95%CI 72 to 86]) and presence (97% [91 to 99]) were 
significantly greater than US (70% [62 to 78], 92% [84 to 96]); a 10% (1 to 18; p=0.027), and 
5% (1 to 9), difference respectively. MRE specificity for SB disease extent (95% [85 to 98]) 
was significantly greater than US (81% [64 to 91]). Sensitivity for active SB disease was 
significantly greater for MRE than US (96% [92 to 99] vs. 90% [82 to 95]), difference 6% (2 
to 11). Overall, there were no significant accuracy differences for colonic disease presence. 
Accuracy in newly diagnosed and relapse patients was similar, although US had significantly 
greater sensitivity for colonic disease than MRE in newly diagnosed patients (67% [49 to 81) 
vs. 47% [31 to 64]), difference 20% (1 to 39). There were no serious adverse events. 
Interpretation 
MRE has higher diagnostic accuracy for the extent and activity of SB Crohn’s disease than 
US when tested in a prospective multi centre cohort trial setting. 
6 
 
Funding  
NIHR Health Technology Assessment  
  
7 
 
 
Introduction 
Small bowel imaging is fundamental for comprehensive phenotyping of Crohn’s disease and 
essential to direct therapeutic strategy.
1
 Barium fluoroscopy has long been the bedrock of 
small bowel investigation, providing detailed mucosal evaluation.
2
 However, in recent years 
enthusiasm has dwindled, and it is replaced increasingly by cross sectional imaging, namely 
computed tomography enterography (CTE), magnetic resonance imaging enterography 
(MRE), and ultrasound (US). Advocates stress that these techniques evaluate the bowel wall 
and beyond, complimenting endoscopic visualisation. As barium fluoroscopy is abandoned, 
dissemination of the various cross-sectional imaging technologies has been relatively 
uncontrolled, despite a paucity of supportive data from methodologically sound prospective 
multi-centre studies. This lack of robust evidence is concerning given the pivotal role 
assumed by small bowel imaging over the lifetime of patients with Crohn’s disease. 
Of the available modalities, MRE and US are preferred
3
 since they avoid irradiating generally 
young patients who require repeat imaging.
4
 Enteric US is longer established,
5
  requires little 
patient preparation, and the technology is widely available. However, questions remain over 
accuracy, particularly in the proximal bowel and deep pelvis,
6
 and perceived inter-observer 
variability.
7
 Conversely, MRE is a more recent innovation,
8
 requires oral contrast and access 
to high technology imaging platforms, which are comparatively restricted in many health care 
settings. 
Although meta-analyses suggest MRE and US have similar accuracy for diagnosing and 
staging Crohn’s disease,6,9-20 the primary literature is of questionable quality. The majority of 
studies are small, single centre,
21
 
17,20
  and few compare tests directly in the same patient, 
despite this being advocated as optimal methodology for diagnostic accuracy studies.
22
 For 
example in their recent meta-analysis, Greenup and al found just one of 33 included studies 
compared MRE and US directly in the same patients.
15
 Also, very few utilise a construct 
reference standard paradigm (panel diagnosis), which incorporates concepts of diagnostic test 
validation based on patient outcomes, and has distinct methodical advantages when a single 
reference standard is elusive.
23
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In order to redress this, we conducted a prospective multicenter trial to elucidate and then 
directly compare the diagnostic accuracy of MRE and US for small bowel Crohn’s disease 
against a construct reference standard incorporating patient follow up. To reflect normal 
clinical practice, we recruited both newly diagnosed patients and those with established 
disease in whom luminal relapse was suspected.  
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Methods 
Trial Design and participants 
The METRIC study is a multicentre, prospective cohort trial comparing the diagnostic 
accuracy of MRE and enteric ultrasound US for the presence, extent and activity of small 
bowel Crohn’s disease in newly diagnosed patients, or patients with established disease and 
suspected relapse, and achieved ethics committee approval in September 2013 (13/SC/0394). 
The trial was supervised by University College London’s Comprehensive Clinical Trials Unit 
and overseen by independent Data Monitoring and Trial Steering Committees. All patients 
recruited gave written informed consent. The full trial protocol has been published,
24
 and can 
be found online (http://www.ucl.ac.uk/cctu/research-areas/gastroenterology/metric). The trial 
is registered with the International Standard Randomised Controlled Trial registry number 
ISRCTN03982913. 
Patients were recruited from 8 UK National Health Service (NHS) teaching and general 
hospitals, representative of institutions likely to implement MRE and US for patient 
management (appendix p2). All sites had an established inflammatory bowel disease service 
and were already performing MRE and US as part of usual clinical practice.  
Patients were eligible for the new diagnosis subgroup if they had been diagnosed with 
Crohn’s disease in the 3 months preceding recruitment based on conventional diagnostic 
criteria, or where Crohn’s disease was strongly suspected based on imaging or endoscopic 
features but pending final diagnosis. Eligible patients had already undergone colonoscopy or 
were awaiting it at recruitment. Patients in whom the final diagnosis was not Crohn’s disease 
were excluded subsequently. 
Patients were eligible for the suspected luminal relapse subgroup if they had established 
Crohn’s disease (for greater than 3 months) and high clinical suspicion of luminal relapse 
based on objective markers of inflammatory activity (CRP >8mg/l or faecal calprotectin 
>100mcg/g), and/or symptoms suggestive of luminal stenosis (including obstructive 
symptoms such as colicky abdominal pain, vomiting), and/or abnormal endoscopy. Eligible 
patients for both arms were aged ≥16. Patients were ineligible if pregnant or if they had 
contraindications to MRI. 
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Suitable patients were identified from outpatient clinics, multi-disciplinary team meetings 
and in-patient wards by members of the local research team, who took informed consent from 
consecutive unselected eligible patients.  A screening log detailed all approached patients, 
and reasons for non-participation, if applicable. Patient demographics and clinical data were 
collated (for example age, sex, Montreal classification [relapse subgroup only], 
disease/symptom duration, medication and surgical history). 
Procedures 
Patients underwent MRE and US in addition to any other enteric imaging or endoscopic 
investigations performed during their usual clinical care.  
MRE was undertaken according to local standard clinical protocols (including the choice of 
oral contrast agent) on either 1·5T or 3T MRI platforms. A minimum dataset of sequences 
was acquired (appendix p3). US was performed by radiologists or sonographers using 
standard platforms and both curvilinear and high-resolution probes, without oral or 
intravenous contrast agents (appendix p4).  
Across all sites, 28 practitioners interpreted the MRE and US studies (27 radiologists and 1 
sonographer). Eight radiologists interpreted MRE only, 3 performed and interpreted US only 
and 16 performed and interpreted US and interpreted MRE. All radiologists were affiliated 
with the British Society of Gastrointestinal and Abdominal Radiology (BSGAR) with 
declared subspecialty interest in gastrointestinal radiology and were either consultant grade or 
post Fellowship of the Royal College of Radiologists, with at least one year of sub-specialty 
training in gastrointestinal radiology. The sonographer had undergone formal training 
according to their sites’ local polices and was performing enteric US routinely and had 20 
years of experience. Radiologists interpreting MRE had a median 10 years of experience 
(Interquartile Range [IQR] 6 to 11) and practitioners interpreting US had a median 8 years of 
experience (IQR 4 to 11). The median number examinations performed per month at each 
recruitment site during the conduct of the trial was 30 (IQR 20 to 45) for MRE and 25 (IQR 
12 to 40) for US. Before trial commencement, a two-day hands-on workshop for investigators 
was held to standardise US technique and agree description of enteric findings.  
MRE and US were interpreted by two different practitioners blinded to the findings of the 
other, and to all other imaging, endoscopic and clinical data other than the cohort to which 
11 
 
the patient was recruited (i.e. new diagnosis or relapse) and surgical history (since this 
information would normally be provided on clinical requests). Using case report forms, 
practitioners noted the presence and activity of Crohn’s disease in the small bowel and colon, 
together with any extra-enteric complications, using established criteria (appendix p5).
6,16,25
 
The segmental location of any disease was also recorded, using standard definitions;
24
 disease 
sites separated by >3cm of normal bowel within a particular segment were recorded 
separately.  Diagnostic confidence for disease presence was scored from 1 to 6, grouped into 
normal (levels 1,2) equivocal (levels 3,4) and abnormal (levels 5,6). A clinical report was 
then generated as per usual clinical practice.  
The findings of all other small bowel imaging or endoscopies performed as part of usual care 
were collected by members of the local research team. These tests were performed and 
interpreted according to usual clinical practice at local sites, without blinding. A case report 
form recorded colonoscopic findings specifically.  
If there was discrepancy between MRE and US for the presence or location of small bowel 
disease, an “arbiter” small bowel investigation was performed if patients had not already 
undergone additional small bowel imaging as part of usual care. Discrepancy was defined as 
terminal ileal disease reported on one of MRE or US in the absence of endoscopic 
visualisation, and/or disease reported in the small bowel upstream of the terminal ileum on 
one of MRE or US. The nature of the additional test was left to local discretion and could 
include for example barium follow through, CTE or capsule endoscopy. Repeat targeted 
unblinded MRE or US were also permitted to resolve discrepancies. 
Where possible, CRP calprotectin and the Harvey Bradshaw index were collected at 
recruitment and repeated between 10 and 20 weeks later.  
Patients were asked if they found MRE and US acceptable and which test attribute they 
considered to be the most important.   
We used the construct reference standard paradigm (panel diagnosis) incorporating the 
concept of clinical test validation, i.e. whether test results are meaningful in practice.
23
  
Specifically, we followed patients’ clinical course for 6 months to assess the impact of MRE 
and US findings on clinical decision making and patient outcomes. Each recruitment site 
convened a series of consensus panels consisting of at least one local gastroenterologist and 
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two radiologists (one local and one from another site); a histopathologist was available if 
required and a member of the trial management group attended to ensure uniformity of 
process. For each patient, the panel considered the images and results of all small bowel 
investigations (including MRE and US) and all additional information accrued over the 
follow-up period including endoscopies, surgical findings, histopathology, HBI, CRP, 
calprotectin (and changes thereof), and clinical course. The panel recorded its opinion as to 
whether small bowel or colonic Crohn’s disease was present, and, if so, whether disease was 
active. All panel decisions were recorded as present/absent, active/inactive with no option of 
an indeterminate outcome. Disease could only be categorised as active if there was at least 
one objective marker of this [(i) ulceration as seen at endoscopy and/or (ii) measured CRP >8 
mg/l and/or (iii) measured calprotectin >250mcg/g and/or (iv) histopathological evidence of 
acute inflammation based on biopsy or surgery within 2 months of trial imaging].  
Outcomes 
The primary outcome was the per patient difference in sensitivity between MRE and US for 
correct identification and localisation of small bowel Crohn’s disease, irrespective of activity, 
i.e. the extent of small bowel disease. To be true positive for disease extent, the index test had 
to correctly locate both the presence and segmental location of disease (terminal ileum, 
ileum, jejunum or duodenum).  Secondary outcomes included specificity for disease extent, 
sensitivity and specificity for small bowel disease presence, the difference in per patient 
sensitivity and specificity for colonic disease presence and extent, and identification of active 
disease. Most outcomes were reported for the new diagnosis and suspected luminal relapse 
subgroups individually, and for the terminal ileum and colon using colonoscopy as a 
standalone reference standard (when available), due to its robustness for identifying disease. 
All outcomes were pre-specified except accuracy for individual small bowel segments 
(duodenum, jejunum, ileum), accuracy for disease presence and extent in the colon, and per 
patient disease activity (small bowel and colonic disease combined), which were exploratory. 
Statistical analysis 
We estimated that a sample size of 210 patients with small bowel disease would give 90% 
power to detect a significant (10%) sensitivity difference for small bowel disease extent 
between MRE (83% based on a sensitivity of 93% and 90%  for disease presence and 
13 
 
location respectively)  and US (73% based on a sensitivity of 88% and 83%  for disease 
presence and location respectively), assuming 68% positivity for both tests and using 
methods for comparative studies.
24,26
 Assuming a 70% prevalence of small bowel disease and 
10% loss to follow up/non-Crohn’s disease diagnosis, gave a target sample size of 334 
patients across both cohorts (167 new diagnosis and 167 relapse). The trial was not powered 
to detect differences between the cohorts, or between bowel segments. 
Disease reported as equivocal was treated as positive in the analysis. The primary outcome 
was calculated per patient. Secondary outcomes for bowel segments were based on all 
segments, excluding those resected at baseline (neo-terminal ileum was considered as the 
“terminal ileum”).  
Direct comparison of sensitivity and specificity differences between MRE and US were 
calculated using bivariate multilevel patient specific (conditional) random effects models, 
from paired data using meqrlogit in STATA 14.2 [College Station, Texas 77845 USA]. When 
models did not converge due to small numbers of patients, McNemar’s comparison of paired 
proportions was used to obtain univariable estimates and exact 95% CI were calculated. 
Analysis by segment used a population averaged random effects model (using logit including 
robust standard errors). Statistical significance was based on 95% CI. There were no missing 
data for per patient diagnosis of disease presence or disease extent, for the reference standard, 
MRE or US. 
Data sharing 
Contact corresponding author 
Role of Funding source 
The primary funder (the National Institute for Health Research) stipulated a diagnostic 
accuracy trial using a cohort design but were not involved in the collection, analysis, or 
interpretation of data, nor in the writing or submitting of this report. The corresponding 
author had full access to all data and final responsibility for the decision to submit for 
publication. 
Results 
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Recruitment commenced December 2013 and completed September 2016. Overall, 518 
patients were assessed for eligibility, of whom 183 were excluded (figure 1). Of the 335 
patients who entered the trial, 51 were excluded subsequently (20 male, median age 30 years 
[IQR 24 to 41]); 31 did not have Crohn’s disease, 2 were lost to follow up, 10 did not 
undergo MRE and/or US, 6 withdrew consent, and 2 newly diagnosed patients underwent 
surgery without colonoscopy. This gave a final cohort of 284 (133 new diagnosis and 151 
relapse), (figure 1, table 1) including 154 (54%) women. Based on the reference standard, 
233 (82%) patients had small bowel Crohn’s disease (thereby meeting sample size 
stipulations), which was active in 209 (90%) (table 2). One hundred and twenty-nine (44%) 
had colonic disease, which was active in 126 (98%). Twenty-one had enteric fistulae, and 7 
had intraabdominal abscess. No serious adverse events were reported. 
In 53 patients (24 new diagnosis, 29 relapse) MRE and US were discrepant for small bowel 
disease presence or location, of whom 48 (91%) had an additional small bowel imaging test 
available to the consensus panel. The range of imaging, endoscopic and biochemical data 
available to the consensus panels is shown in appendix p6.  
MRE sensitivity for small bowel disease extent (i.e. presence and correct segmental location), 
was 80% (95% CI 72 to 86) compared to 70% (62 to 78) for US, a difference of 10% (1 to 
18; p=0.027), which was statistically significant (table 3, figure 2 appendix p7). MRE 
specificity for small bowel disease extent was also significantly greater than US: 95% (85 to 
98) vs. 81% (64 to 91) respectively, a difference of 14% (1 to 27). 
MRE sensitivity for small bowel disease presence, regardless of location was 97% (91 to 99), 
significantly greater than US (92% [84 to 96]), a difference of 5% (1 to 9), (table 3, figure 2).  
There were no significant differences in sensitivity or specificity between MRE and US for 
colonic disease extent or presence (table 3, figure 2).  
The detection rate for individual small bowel and colonic segments is given in supplementary 
appendix p8. Although the trial was not powered to detect differences on a segmental level, 
MRE was significantly more sensitive than US for ileal (84% [67 to 93] vs 56% [38 to 73]) 
and rectal disease (44% [32 to 58] vs. 22% [13 to 35]). 
15 
 
Sensitivities of MRE and US for small bowel disease presence and extent in the new and 
relapse patient cohorts were very similar to those estimated across all patients (table 4). US 
however had significantly greater sensitivity for colonic disease presence than MRE in the 
new patient cohort (67% [49 to 81] vs. 47% [31 to 64]), a difference 20% (1 to 39). For both 
tests, sensitivity for colonic disease tended to be higher in the relapse patient cohort (table 4), 
although the estimated sensitivity for colonic disease extent was poor. 
MRE sensitivity for active small bowel disease was 96% (92 to 99) compared to 90% (82 to 
95) for US, a significant difference of 6% (2 to 11) (table 5). Specificity for active small 
bowel disease and for active colonic disease were not significantly different between tests 
(table 5). 
Sensitivity and specificity for active disease split by patient cohort were very similar to those 
estimated across all patients (appendix p9). 
MRE detected 5/7 (71%) abscesses and 18/21 (86%) patients with enteric fistulae compared 
to 3/7 (43%) and 11/21 (52%) for US respectively.   
Against a colonoscopic standard of reference (available in 186 patients), MRE had a 
sensitivity of 97% (91 to 99), for terminal ileal disease presence compared to a sensitivity of 
91% (79 to 97) for US, a difference of 6% (-1 to 12) (appendix p10). Sensitivity for colonic 
disease presence was modest for both MRE and US (41% [26 to 58] and 49% (33 to 65]), and 
not statistically different. 
Of responding patients, 128/145 (88%) and 144/146 (99%) rated MRE and US as acceptable, 
respectively.  Diagnostic accuracy was rated as the most important test attribute. 
  
 
Discussion 
At the time of writing, METRIC is the largest prospective multicenter trial directly 
comparing diagnostic accuracy of MRE and US for the presence, extent and activity of 
Crohn’s disease in the same patients. We found both MRE and US highly accurate for 
detecting small bowel Crohn’s disease, achieving 97% and 92% sensitivity respectively. 
16 
 
Barium fluoroscopy has long been advocated as a sensitive test for mucosal disease 
inaccessible to endoscopy, although support is limited to a handful of small studies
2
 and 
accuracy is increasingly questioned.
27
 Conversely, against a rigorous ileo-colonoscopic 
reference standard, we found MRE and US achieved 97% and 91% sensitivity for terminal 
ileal disease, strongly supporting their transition to first line investigations, and positioning 
them as competitive and viable diagnostic alternatives to invasive ileo colonoscopy. 
Of the two, we found MRE had significantly higher sensitivity and specificity than US for 
small bowel extent, and higher sensitivity for disease presence. Overall, there was no 
significant difference in diagnostic accuracy for colonic disease (consistently lower than for 
small bowel disease), although US had greater sensitivity than MRE in newly diagnosed 
patients. 
Our primary outcome combined those aspects necessary to stage small bowel Crohn’s disease 
correctly, i.e. is disease present and, if so, where? Both presence and extent dictate 
subsequent therapeutic strategy. For example, the finding of additional proximal small bowel 
disease may tip the balance towards medical rather than surgical intervention in the face of 
otherwise limited terminal ileal disease. As expected, sensitivity for disease extent was lower 
than that for disease detection alone.  
We found detection rates at the upper end of estimates from prior meta-analyses.
6,9-20
 Dong et 
al
12
 estimated sensitivity and specificity of US at 88% and 97% respectively, while Liu et al
17
 
reported corresponding figures of 86% and 93% for MRE. However, the primary literature is 
markedly heterogeneous, which impacts on validity of point estimates. Most studies are 
single centre, typically recruit fewer than 50 patients, and many are methodologically poor. 
17,21
  Direct comparison of diagnostic tests in the same patients is advocated as the optimal 
methodology for diagnostic accuracy studies
22
 as differences are attributable directly to the 
tests and not differences between participants or study methods. Such head-to-head 
comparisons are rare in the literature.
15
 Reference standards may also be applied 
inconsistently, with endoscopy, surgery, and imaging all variably employed. For example, in 
a comparative study with US, Castiglione et al used MRE without any additional reference 
standard in many recruits.
28
 The potential for incorporation bias is self-evident. 
We used the construct reference standard paradigm (panel diagnosis), which incorporates 
multiple data sources with clinical outcome. 
23
 Although such an approach does have 
17 
 
limitations, including potential panel bias, it is considered a very robust methodology for 
diagnostic accuracy studies where a single external reference standard is elusive.
23
 To reduce 
incorporation bias, patients without supplementary small bowel imaging underwent a third 
small bowel investigation whenever discrepancy between MRE and US arose.  It is notable 
than when our analysis was limited to an ileo-colonoscopic reference standard, any 
differences in accuracy between MRE and US closely mirrored those found using the 
consensus panel reference.     
We recruited approximately equally from two patient cohorts; new diagnoses of Crohn’s 
disease and those with established disease, suffering relapse. Both are clinically distinct and 
important, and may manifest with differing disease phenotypes; prevalence of stricturing and 
penetrating disease increases with time.
29
 Noting that METRIC was not powered to detect 
differences between these two cohorts, we found that sensitivity for small bowel disease was 
similar, although specificity tended to be a lower in those with relapse. Conversely, 
sensitivity for colonic disease was higher in the relapse cohort, but was still poor for colonic 
disease extent (around 30%).   
In newly diagnosed patients US achieved significantly greater sensitivity for colonic disease 
than MRE (67% vs 47%). Optimised colonic evaluation using MRE requires purgation and 
fluid distension,
30
 which are both omitted from routine MRE protocols, whereas, in general, 
US relies on evaluating the manually compressed uncleansed colon wall. Accuracy for both 
techniques in the colon still falls short of colonoscopy, and in the case of MRE is somewhat 
lower than previously reported.
31,32
  By way of explanation, ileo-colonoscopy and 
histopathology results were available to the consensus reference panel for most patients 
(particularly those newly diagnosed), and are exquisitely sensitive for early mucosal disease, 
beyond the resolution of cross sectional imaging. Our outcomes were dependent on disease 
presence regardless of severity.  Data from existing single center explanatory studies either 
use cohorts enriched with more advanced colonic disease
32
, or report sensitivity for deep 
rather than superficial mucosal disease.
31
 
Most patients found MRE and US acceptable, although more so for US than MRE. This is 
perhaps expected given the different attributes of the two tests. Patients however rated 
diagnostic accuracy as the most important test attribute, consist with previous work,
33
 
suggesting patients will tolerate greater discomfort for improved test performance.  
18 
 
Our trial does have limitations. METRIC was conceived as a large pragmatic trial
34
 since the 
literature is replete with small explanatory studies. We recruited from a range of hospital 
settings, both teaching and district general, and used local imaging protocols to enhance 
generalisability. The 28 practitioners all declared a specialist interest in gastrointestinal 
radiology and were representative of those reporting NHS small bowel imaging in terms of 
training and experience. We specifically avoided using a small number of highly experienced 
practitioners since they would not represent a national workforce. We do however 
acknowledge that specialist practitioners working in high volume practices may achieve 
sensitivities in excess of our findings. Imaging was interpreted according to local clinical 
practice in order to mirror “real world” procedures within the NHS, and enhance 
generalisability of our results. We acknowledge that blinding practitioners to individual 
patient history does not mirror usual clinical practice, but this precaution was necessary to 
isolate diagnostic test accuracy as far as possible. We cannot however exclude occasional 
inadvertent unblinding of reporting practitioners.  Recruited patients were representative of 
those undergoing MRE and US in daily practice, although we did exclude pregnant women, 
patients undergoing routine therapeutic response assessment, and patients with 
contraindications to MRI. Our results are therefore highly likely to extrapolate across the 
NHS and similar health care settings. The prevalence of active disease was predictably high 
given our recruited patient cohorts. The reported high specificity of MRE and US should 
therefore be viewed in this context. 
We did not standardise the third small bowel investigation whenever discrepancy between 
MRE and US arose, and this was left to the discretion of the recruitment site. Direct mucosal 
visualisation is possible using push enteroscopy
35
 or capsule endoscopy
36
 but to insist on such 
investigations was not practicable in the setting of a pragmatic multicenter trial, given their 
cost, relatively limited availability and likely negative impact on patient compliance and 
safety. Push enteroscopy for example is a highly invasive and  specialised investigation, and 
attracts a small but well documented risk of major complications such as perforation.
37
 
Similarly the risk of capsule retention is around 8% in those with known Crohn’s disease,38 
and specificity is questioned.
39
 We also  considered that the invasive nature of 
capsule/enteroscopy would result in considerable spectrum bias relating to differences 
between patients who would and would not agree to consent (even were they available and 
affordable). 
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To reduce incorporation bias from MRE or US, we required at least one independent 
biochemical, endoscopic or histological marker of disease activity before a patient could be 
“labeled” with active small bowel or colonic disease. Biochemical markers such as 
calprotectin and CRP provide evidence at the patient level, but the reference standard 
consensus panel also had access to a range of additional clinical material when making their 
decision, including endoscopy and a range of small bowel imaging investigations.  
There is data suggesting that diagnostic accuracy of US can be improved with an oral contrast 
load (small intestine contrast enhanced US [SICUS]), particularly for luminal stenosis, and 
intravenous contrast enhanced US (CEUS) may have utility for assessing disease activity.
40
 
However, neither SICUS and CEUS have disseminated as first line investigations outside 
specialist units, and if used, are often employed as problem solving tools.
40,41
 Standard US is 
overwhelmingly the most commonly employed technique in routine clinical practice. Future 
prospective research could consider inclusion of both SICUS and CEUS in trial design. 
Diagnostic accuracy is clearly paramount when patients are investigated but interobserver 
variability, and cost effectiveness are also of great importance, and will be reported 
elsewhere, together with a more detailed consideration of patient experience.    
In summary, we found that both US and MRE achieve excellent diagnostic accuracy for the 
extent and activity of small bowel Crohn’s disease in both newly diagnosed patients and 
those suffering relapse and both tests are valid first-line investigations. In a national health 
service setting, MRE is generally the preferred radiological investigation when available 
because its sensitivity and specificity exceed US significantly.  
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Tables 
Table 1 Demographics of final trial cohort 
 
  New diagnosis [n (%)] 
N=133 
Relapse [n (%)] 
N=151 
    
Sex Male  69 (52) 61 (40) 
 Female 64 (48) 90 (60) 
Age (years) 16-25  49 (36) 46 (30) 
 26-35 32 (24) 36 (24) 
 36-45 18 (14) 28 (19) 
 >45 34 (26) 41 (27) 
Disease duration <1 year NA 5 (3) 
 1-5 years NA 45 (30) 
 6-10 years NA 39 (26) 
 >10 years NA 62 (41) 
Disease location (Montreal 
classification)a 
L1 NA 56 (37) 
 L2 NA 17 (11) 
 L3 NA 74 (49) 
 L4 NA 4 (3) 
Disease Behaviour (Montreal 
classification) 
B1 NA 80 (53) 
 B1p NA 4 (3) 
 B2 NA 52 (34) 
 B2p NA 1 (1) 
 B3 NA 12 (8) 
 B3p NA 2 (1) 
Medicationc None 62 (47) 32 (21) 
 5-ASA 21 (16) 26 (17) 
 Steroids  48 (36) 28 (19) 
 Immunomodulators 16 (12) 75 (50) 
 Anti-TNF antibodies 5 (4) 42 (28) 
Previous enteric resection Yes 1 (1)b 
 
72 (48) 
a 
Montreal classification not collected for new diagnosis patients 
b Surgical resection for inflammatory mass 1 year prior to Crohn’s disease diagnosis 
c Patients could take more than one type of medication  
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Table 2 Patient characteristics: disease presence and activity-consensus reference 
standard 
 
 New diagnosis (n=133) 
[n (%)] 
Suspected relapse  (n=151) 
[n (%)] 
Full cohort (n=284) 
[n (%)} 
    
Disease presence    
Small bowel disease present 111 (83) 122 (81) 233 (82) 
Colonic disease present 77 (58) 52 (34) 129 (45) 
    
Isolated small bowel disease present 56 (42) 85 (56) 141 (50) 
Isolated colonic disease present 22 (17) 15 (10) 37 (13) 
Both small bowel and colonic disease present 55 (41) 37 (25) 92 (32) 
Total number patients with disease present 133 (100) 137 (91) 270 (95) 
    
Median number of involved small bowel 
segments  
[median (IQR), max] 
1 (1 to 1), 4 1 (1 to 1), 3 1 (1 to1), 4 
Median number of involved colonic segments  
[median (IQR), max] 
1 (0 to 3), 6 0 (0 to 1), 6 0 (0 to 2), 6 
    
Disease activity    
Small bowel disease active 104 (94) 105 (86) 209 (90) 
Colonic disease active 76 (99) 50 (96) 126 (98) 
Total number patients with disease active 130 (98) 121 (88) 251 (93) 
  Criteria for activitya     
   Ulceration at endoscopy 71 (55) 26 (21) 97 (39) 
   CRP >8 mg/l 47 (36) 57 (47) 104 (41) 
   Calprotectin >250 mcg/g 
41 (32) 43 (36) 84 (33) 
   Histological evidence of activity 100 (77) 36 (30) 136 (54) 
a Patients could meet more than one criteria for disease activity 
IQR refers to interquartile range 
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Table 3 Per patient sensitivity and specificity for disease presence and extent against the 
consensus reference standard. Both patient cohorts combined.  
 Sensitivity % (CI 95%) Specificity % (CI 95%) 
 Number of 
disease 
positive a 
MRE US Difference 
(P value) 
Number 
disease 
negative a 
MRE US Difference 
(P value) 
Small bowel 
disease extentb 
233 80 
(72 to 86) 
70 
(62 to 78) 
10 
(1 to 18)      
p=0.027 
51 95 
(85 to 98) 
81 
(64 to 91) 
14 
(1 to 27) 
p=0.039 
Small bowel 
disease 
presence 
233 97 
(91 to 99) 
92 
(84 to 96) 
5 
(1 to 9) 
p=0.025 
51 96 
(86 to 99) 
84 
(65 to 94) 
12 
(0 to 25) 
p=0.054 
Colonic 
disease extentb 
129 22 
(14 to 32) 
17 
(10 to 27) 
5 
(-5 to 15)     
p=0.332 
155 93 
(87 to 97) 
93 
(87 to 97) 
0 
(-5 to 5) 
p=1.000 
Colonic 
disease 
presence 
129 64 
(50 to 75) 
73 
(59 to 83) 
-9 
(-23 to 5)    
p=0.202 
155 96 
(90 to 98) 
96 
(90 to 98) 
0 
(-3 to 3) 
p=1.000 
Small bowel 
and colonic 
disease extentb 
270 44 
(36 to 54) 
29 
(21 to 38) 
16 
(6 to 25)      
p=0.002 
14 80 
(42 to 96) 
61 
(23 to 89) 
19 
(-20 to 59) 
p=0.337 
Small bowel 
and colonic 
disease 
presencec 
270 78 
(70 to 85) 
71 
(62 to 79) 
7 
(-2 to 15)     
p=0.117 
14 80 
(42 to 96) 
61 
(23 to 89) 
19 
(-20 to 59) 
p=0.335 
a Patients by consensus reference standard 
b Agreement with reference standard for disease presence and segmental location 
c Agreement with reference standard for disease presence (patients with disease in the small bowel, colon or both) 
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Table 4 
Sensitivity and specificity for disease presence and extent against the consensus reference standard, 
according to patient cohort.  
 New diagnosis 
N=133 
Suspected relapse 
N=151 
 DP,DNa Sensitivity % (CI 95%) Specificity % (CI 95%) DP,DNa Sensitivity % (CI 95%) Specificity % (CI 95%) 
  MRE US Difference 
 
MRE US Difference 
 
 MRE US Difference 
 
MRE US Difference 
 
Small 
bowel 
disease 
extentb 
111,22 77 
(66 
to 
86) 
66 
(54 
to 
77) 
11 
(-2 to 24) 
 
98 
(82 
to 
100) 
88 
(64 
to 
97) 
10 
(-5 to 24)      
122,29 82 
(72 
to 
89) 
74 
(62 
to 
83) 
8 
(-3 to 19)      
92 
(74 
to 
98) 
75 
(50 
to 
90) 
17 
(-3 to 37)      
Small 
bowel 
disease 
presence 
111,22 96 
(89 
to 
99) 
92 
(82 
to 
96) 
4 
(-1 to 10) 
 
99 
(84 
to 
100) 
91 
(65 
to 
98) 
8 
(-5 to 21)      
122,29 97 
(91 
to 
99) 
92 
(82 
to 
96) 
5 
(0 to 11) 
 
94 
(76 
to 
99) 
78 
(50 
to 
92) 
16 
(-4 to 36) 
 
Colonic 
disease 
extentb 
77,56 17 
(9 to 
30) 
9 
(4 
to 
19) 
8 
(-2 to 19)      
93 
(82 
to 
98) 
92 
(80 
to 
97) 
1 
(-7 to 10)      
52,99 31 
(17 
to 
48) 
33 
(19 
to 
51) 
-2 
(-22 to 
17)     
93 
(85 
to 
97) 
94 
(86 
to 
97) 
-1 
(-7 to 5)     
Colonic 
disease 
presence 
77,56 47 
(31 
to 
64) 
67 
(49 
to 
81) 
-20 
(-39 to -1) 
 
96 
(86 
to 
99) 
95 
(84 
to 
98) 
1 
(-5 to 7)      
52,99 84 
(67 
to 
94) 
80 
(61 
to 
91) 
4 
(-11 to 
20)      
96 
(88 
to 
98) 
 
95 
(89 
to 
99) 
-1 
(-5 to 4)     
Small 
bowel 
and 
colonic 
disease 
extentb 
133,0 33 
(22 
to 
46) 
20 
(12 
to 
30) 
13 
(1 to 26)       
N/A N/A N/A 137,14 56 
(43 
to 
68) 
40 
(28 
to 
52) 
16 
(2 to 31)       
 
80 
(42 
to 
96) 
61 
(24 
to 
88) 
19 
(-20 to 
59)      
Small 
bowel 
and 
colonic 
disease 
presencec 
133,0 65 
(52 
to 
76) 
66 
(53 
to 
77) 
-1 
(-15 to 
13)     
N/A N/A N/A 137,14 88 
(79 
to 
93) 
76 
(64 
to 
85) 
12 
(2 to 22)      
  
80 
(42 
to 
96) 
61 
(23 
to 
89) 
19 
(-20 to 
59)      
a Disease positive (DP), Disease negative (DN) patients by consensus reference standard 
b Agreement with reference standard for disease presence and segmental location 
c Agreement with reference standard for disease presence (patients with disease in the small bowel, colon or both) 
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Table 5 
Per patient sensitivity and specificity for the presence of active disease versus the consensus reference 
standard. Both patient cohorts combined.  
 Sensitivity % (CI 95%) Specificity % (CI 95%) 
 Number 
active 
diseasea 
MRE US Difference 
(P value) 
Number 
inactive 
diseasea 
MRE US Difference 
(P value) 
Active small 
bowel diseaseb 
209 96 
(92 to 99) 
90 
(82 to 95) 
6 
(2 to 11) 
p=0.010 
75 83 
(68 to 92) 
77 
(60 to 88) 
6 
(-8 to 20) 
p= 0.376 
Active Colonic 
diseaseb 
126 63 
(48 to 76) 
66 
(51 to 79) 
-3 
(-18 to 13) 
p=0.735 
158 
 
97 
(91 to 99) 
98 
(94 to 99) 
-1 
(-4 to 1) 
p=0.304 
Active Small 
bowel and 
colonic diseasec  
251 77 
(68 to 85) 
66 
(56 to 75) 
11 
(1 to 21) 
p=0.024 
33 28 
(10 to 56) 
28 
(10 to 56) 
0  
(-26 to 26) 
p=1.000 
a Patients by consensus reference standard 
b Agreement with reference standard for disease active  
c Agreement with reference standard for active disease presence (patients with disease in the small bowel, colon or both) 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Patient flow diagram 
  
518 Screened participants  
 
183 Excluded 
58 declined participation 
28 failed to respond to invitation 
22 non-Crohn’s diagnosis 
20 Unable to complete MRE and/or 
US in timely fashion 
13 Not meet trial eligibility criteria 
(relapse cohort) based on low CRP 
8 contraindication to MRE 
7 not able give informed consent 
5 Previous recruitment or declined 
approach 
4 moved/lived far away 
4 Proceeded straight to surgery prior 
to colonoscopy (new diagnosis cohort) 
2 Newly diagnosed more than 3 
months previously 
2 under 16 years old 
10 unknown 
 
335 Recruited participants  
 
284 Included participants  
51 Withdrawals 
31 final diagnoses other than 
Crohn’s 
5 did not undergo MRE 
3 did not undergo US 
2 did not undergo MRE or US  
3 withdrew consent 
3 no longer wished to 
participate in follow up 
2 lost to follow up 
2 Underwent surgery without 
colonoscopy 
 
 
 
133 Newly diagnosed participants 
 
151 Suspected relapse participants 
 
Index tests 
151 MRE and US  
 
Index tests 
133 MRE and US  
 
Reference standard 
133 Consensus panel at 6 months 
 
Reference standard 
151 Consensus panel at 6 months 
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Figure 2 MRE and US sensitivity and specificity for small bowel and colonic disease extent and presence 
against the consensus reference standard 
 
